Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rhea-AI Summary

Stoke Therapeutics (NASDAQ: STOK) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its Dravet syndrome treatment program. The company's lead investigational medicine, zorevunersen, is advancing to Phase 3 EMPEROR study in Q2 2025.

Key financial highlights include:

• Cash position of $246.7 million as of December 31, 2024
• Full-year 2024 revenue of $36.6 million, up from $8.8 million in 2023
• Net loss of $89.0 million ($1.65 per share) in 2024, improved from $104.7 million in 2023

Notable developments include a new collaboration with Biogen, FDA Breakthrough Therapy Designation for zorevunersen, and positive clinical data presented at AES 2024. The company expects its current cash position, combined with the $165 million Biogen collaboration upfront payment, to fund operations until mid-2028.

Positive

• Secured $165M upfront payment from Biogen collaboration
• Revenue increased 316% to $36.6M in 2024
• Net loss improved by 15% year-over-year
• Strong cash position of $246.7M plus Biogen payment extends runway to mid-2028
• Received FDA Breakthrough Therapy Designation for zorevunersen

Negative

• Operating expenses increased in both R&D and G&A segments
• Still operating at a significant net loss of $89.0M
• CEO Edward Kaye stepping down from leadership position

Insights

Biotechnology Financial Analyst

Stoke Therapeutics' year-end financial report presents a notably strengthened balance sheet that transforms its operational outlook. The $246.7 million cash position, bolstered by the $165 million upfront payment from Biogen, creates an extraordinarily long runway to mid-2028 - a level of financial security rarely seen in clinical-stage biotechnology companies.

Revenue recognition of $36.6 million for 2024 (up from $8.8 million in 2023) demonstrates successful execution of the Acadia collaboration. The net loss improvement to $89.0 million ($1.65 per share) from $104.7 million ($2.38 per share) shows improving financial metrics despite expected increases in R&D ($89.1 million) and G&A expenses ($48.8 million) associated with late-stage program advancement.

The Biogen collaboration represents a strategic geographic split that maintains full commercial control in North America while leveraging Biogen's infrastructure globally - a model that balances ownership of high-value markets with operational efficiency. This strategic decision enhances Stoke's value proposition by retaining significant commercial rights while adding expert commercialization capabilities and additional capital.

With secured funding through Phase 3 completion and potential commercialization, Stoke has effectively derisked its financial position at a critical development inflection point, allowing full focus on clinical execution rather than capital raising.

Rare Disease Development Expert

The regulatory and clinical milestones achieved for zorevunersen substantially validate Stoke's RNA-based approach for Dravet syndrome. The FDA's Breakthrough Therapy Designation represents significant external validation of the program's potential, as this designation is reserved for treatments demonstrating substantial improvement over available therapies on clinically significant endpoints.

Equally important is the global regulatory alignment across FDA, European, and Japanese agencies regarding the Phase 3 EMPEROR study design. This harmonized approach creates a clear, efficient path to potential global approvals through a single pivotal program, avoiding the common pitfall of differing regional requirements that can delay international commercialization.

The positive data from open-label extension studies presented at AES 2024 further strengthens the clinical profile, specifically supporting the Phase 3 dosing regimen. For Dravet syndrome - a severe, treatment-resistant epilepsy with significant unmet need - zorevunersen's mechanism addressing the underlying SCN1A genetic cause rather than symptomatically treating seizures represents a paradigm shift in treatment approach.

While the CEO transition creates some uncertainty, the timing after securing the Biogen partnership and regulatory alignment but before Phase 3 initiation suggests a strategic handoff at an appropriate inflection point. The retention of Dr. Kaye as an advisor and board member provides important continuity for this critical development phase.

With the EMPEROR study on track to initiate in Q2 2025, Stoke has successfully navigated the complex path from discovery to pivotal development for a novel genetic medicine.

– Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 –

– As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $165 million upfront and eligible proceeds from Biogen collaboration anticipated to fund operations to mid-2028 –

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the full year ended December 31, 2024 and provided business updates.

“Recent milestones – including Breakthrough Therapy Designation, positive data supporting our Phase 3 dosing regimen and global regulatory alignment – have catalyzed the Dravet community and put us on track to initiate EMPEROR in the second quarter,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “The potential of zorevunersen to change the course of Dravet syndrome by addressing its underlying cause is becoming increasingly recognized. Our recent collaboration with Biogen brings complementary expertise in neurology and the global commercialization of high-value medicines for rare genetic diseases – expertise that will help us deliver faster for patients and maximize value. With a strong financial position, we are well-capitalized to advance through Phase 3 and prepare for launch readiness.”

Recent Program Highlights and Additional Corporate Updates

• Separately today, the Company announced that Dr. Edward M. Kaye has decided to step down as Chief Executive Officer of Stoke Therapeutics. After seven years of successful leadership and taking the company from a startup to a late-stage clinical development company, Dr. Kaye will transition to an advisory role and continue to serve as a Director.
• In February, the Company entered into a collaboration with Biogen to develop and commercialize zorevunersen for the treatment of Dravet syndrome. The Company retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights.
• In January, the Company announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following successful alignment with regulatory agencies in the United States, Europe, and Japan.
• In December, the Company shared new positive data from the open-label extension (OLE) studies of zorevunersen in children and adolescents with Dravet syndrome at American Epilepsy Society (AES) 2024 Annual Meeting.
• In December, the Company announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in the SCN1A gene.

Year End 2024 Financial Results

• As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities, which, along with the $165 million upfront payment received in March 2025 and other eligible cash flows from the Biogen collaboration, we anticipate will fund operations to mid-2028.
• Revenue recognized for upfront license fees and services provided from the License and Collaboration Agreement with Acadia Pharmaceuticals for the year ended December 31, 2024 was $36.6 million, compared to $8.8 million, for the year ended December 31, 2023.
• Net loss for the year ended December 31, 2024 was $89.0 million, or $1.65 per share, compared to $104.7 million, or $2.38 per share for 2023.
• Research and development expenses for the year ended December 31, 2024 were $89.1 million, compared to $82.2 million for 2023.
• General and administrative expenses for the year ended December 31, 2024 were $48.8 million, compared to $41.3 million for 2023.
• The increase in operating expenses for the year ended December 31, 2024 compared to the same period in 2023 primarily relates to increases in costs associated with personnel, third party contracts, consulting, facilities and other costs associated with development activities for zorevunersen and STK-002, research on additional therapeutics and growing a public corporation.

Fourth Quarter 2024 Financial Results

• Revenue recognized for upfront license fees and services provided from the License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended December 31, 2024 was $22.6 million, compared to $2.8 million for the same period in 2023.
• Net loss for the three months ended December 31, 2024 was $10.5 million, or $0.18 per share, compared to $27.0 million, or $0.60 per share, for the same period in 2023.
• Research and development expenses for the three months ended December 31, 2024 were $23.4 million, compared to $21.8 million for the same period in 2023.
• General and administrative expenses for the three months ended December 31, 2024 were $12.8 million, compared to $10.6 million for the same period in 2023.
• The increase in operating expenses for the three months ended December 31, 2024 compared to the same period in 2023 primarily relates to increases in costs associated with personnel, third party contracts, consulting, facilities and other costs associated with development activities for zorevunersen and STK-002, research on additional therapeutics and growing a public corporation.

About Dravet Syndrome
Dravet syndrome is a severe developmental and epileptic encephalopathy characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments. Most cases of Dravet are caused by mutations in one copy of the SCN1A gene, leading to insufficient levels of NaV1.1 protein in neuronal cells in the brain. More than 90 percent of patients continue to experience seizures despite treatment with the best available anti-seizure medicines. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. Developmental and cognitive impairments often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP. Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S., UK, EU-4 and Japan.

About Zorevunersen
Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing NaV1.1 protein production in brain cells from the non-mutated (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition, and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A gene.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is expected to enter Phase 3 development in 2025. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for the Company’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the receipt of potential cashflows under the collaboration with Biogen; the design, timing and results of the Phase 3 EMPEROR study; the timing and expected progress of regulatory filings and regulatory decisions; the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; the Company’s cash runway; and the expectations regarding the collaborations. Statements including words such as “anticipate,” “expect,” “plan,” “will,” or “may” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause the Company’s results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company’s ability to advance, obtain regulatory approval and ultimately commercialize its product candidates; that if Biogen were to breach or terminate the collaboration, the Company would not obtain the anticipated financial or other benefits; the possibility that the Company and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; the Company’s ability to protect its intellectual property; the Company’s ability to fund development activities and achieve development goals through mid-2028; and the other risks and uncertainties described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, its quarterly reports on Form 10-Q, and the other documents it files with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Financial Tables Follow

Stoke Therapeutics, Inc. and subsidiary Consolidated balance sheets (in thousands, except share and per share amounts)
		As of December 31,
		2024				2023
Assets
Current assets:
Cash and cash equivalents		$	127,983			$	191,442
Marketable securities - short term			88,916				9,952
Prepaid expenses			11,117				11,320
Other current assets			3,965				2,561
Restricted cash - short term			75				—
Interest receivable			700				64
Total current assets		$	232,756			$	215,339
Restricted cash - long term			721				569
Operating lease right-of-use assets			4,345				6,611
Marketable securities - long term			29,824				—
Property and equipment, net			3,909				5,823
Total assets		$	271,555			$	228,342
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$	2,498			$	1,695
Accrued and other current liabilities			18,567				13,815
Deferred revenue - current portion			18,991				15,309
Total current liabilities		$	40,056			$	30,819
Deferred revenue - net of current portion			—				33,074
Other long term liabilities			2,478				4,884
Total long term liabilities		$	2,478			$	37,958
Total liabilities		$	42,534			$	68,777
Commitments and contingencies
Stockholders’ equity
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 54,032,826 and 45,918,233 shares issued and outstanding as of December 31, 2024 and 2023, respectively			5				5
Additional paid-in capital			719,997				561,433
Accumulated other comprehensive loss			(151	)			(24	)
Accumulated deficit			(490,830	)			(401,849	)
Total stockholders’ equity		$	229,021			$	159,565
Total liabilities and stockholders’ equity		$	271,555			$	228,342

Stoke Therapeutics, Inc. and subsidiary Consolidated statements of operations and comprehensive loss (in thousands, except share and per share amounts)
		Three Months Ended December 31, (unaudited)								Year Ended December 31,
		2024				2023				2024				2023
Revenue		$	22,614			$	2,801			$	36,555			$	8,780
Operating expenses:
Research and development			23,424				21,778				89,133				82,231
General and administrative			12,844				10,610				48,794				41,322
Total operating expenses			36,268				32,388				137,927				123,553
Loss from operations			(13,654	)			(29,587	)			(101,372	)			(114,773	)
Other income (expense):
Interest income (expense), net			2,971				2,587				12,638				9,908
Other income (expense), net			200				42				(247	)			166
Total other income (expense)			3,171				2,629				12,391				10,074
Net loss		$	(10,483	)		$	(26,958	)		$	(88,981	)		$	(104,699	)
Net loss per share—basic and diluted		$	(0.18	)		$	(0.60	)		$	(1.65	)		$	(2.38	)
Weighted average common shares outstanding—basic and diluted			57,029,296				44,958,894				54,008,883				43,994,862
Comprehensive loss:
Net loss		$	(10,483	)		$	(26,958	)		$	(88,981	)		$	(104,699	)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities			(317	)			122				(127	)			1,151
Total other comprehensive gain (loss)		$	(317	)		$	122			$	(127	)		$	1,151
Comprehensive loss		$	(10,800	)		$	(26,836	)		$	(89,108	)		$	(103,548	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250318007984/en/

Stoke Media & Investor Contacts:

Dawn Kalmar

Chief Communications Officer

dkalmar@stoketherapeutics.com

781-303-8302

Doug Snow

Director, Communications & Investor Relations

IR@stoketherapeutics.com

508-642-6485

Source: Stoke Therapeutics, Inc.

FAQ

What is the current cash position of STOK and how long will it last?

STOK has $246.7M in cash as of Dec 2024, which combined with $165M Biogen payment will fund operations to mid-2028.

How did STOK's revenue change in 2024 compared to 2023?

Revenue increased to $36.6M in 2024 from $8.8M in 2023, primarily from the Acadia Pharmaceuticals agreement.

When will STOK begin the Phase 3 EMPEROR study for zorevunersen?

The Phase 3 EMPEROR study is scheduled to initiate in the second quarter of 2025.

What are the terms of STOK's collaboration with Biogen for zorevunersen?

STOK retains rights in US, Canada, and Mexico, while Biogen gets exclusive commercialization rights for rest of world.

How much did STOK's net loss improve in 2024?

Net loss improved to $89.0M ($1.65 per share) in 2024 from $104.7M ($2.38 per share) in 2023.